Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists

Dermatology

Volumn 219, Issue 1, 2009, Pages 59-62

  Thielen, A M ^a,b   Barde, C ^a   Saurat, J H ^a   Laffitte, E ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Dermatology Department   (Switzerland)

Author keywords

Adalimumab; Dose escalation; Infliximab; Sarcoidosis; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; CHLOROQUINE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PENTOXIFYLLINE; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; PRIORITY JOURNAL; REFRACTORY CHRONIC CUTANEOUS SARCOIDOSIS; SARCOIDOSIS; SKIN MANIFESTATION; STANDARD; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; SARCOIDOSIS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67651092122     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000221005     Document Type: Article

References (17)

1. Badgwell C, Rosen T: Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol 2007;56:69-83.
2. Mahnke N, Medve-Koenigs K, Megahed M, Neumann NJ: Medium-dose UV-A1 phototherapy. Successful treatment of cutaneous sarcoidosis. Hautarzt 2003;54:364-366.
3. Sweiss NJ, Curran J, Baughman RP: Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol 2007;25:341-346. (Pubitemid 46856834)
4. Mallbris L, Ljungberg A, Hedblad MA, et al: Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-α therapy. J Am Acad Dermatol 2003;48:290-293. (Pubitemid 36232335)
5. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006;25:596-597.
6. Heffernan M, Anadkat MJ: Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005;141:910-911. (Pubitemid 41058083)
7. Stagaki E, Mountford WK, Lackland DT, Judson MA: The treatment of lupus pernio: the results of 116 treatment courses in 54 patients. Chest 2009;135:468-476.
8. Heffernan MP, Smith DI: Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol 2006;142:17-19. (Pubitemid 43107354)
9. Philips MA, Lynch J, Azmi FH: Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol 2005;53:917. (Pubitemid 41501405)
10. Mitoma H, Horiuchi T, Tsukamoto H, et al: Mechanisms for cytotoxic effects of antitumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells. Arthritis Rheum 2008;58:1248-1257.
11. Metyas SK, Tadros RM, Arkfeld DG: Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis. Rheumatol Int 2009;29:437-439.
12. Toussirot E, Pertuiset E, Kantelip B, Wendling D: Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471-475. (Pubitemid 352003220)
13. Ishiguro T, Takayanagi N, Kurashima K, et al: Development of sarcoidosis during etanercept therapy. Intern Med 2008;47:1021-1025.
14. González-López MA, Blanco R, González-Vela MC, et al: Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006;55:817-820.
15. Kristensen LE, Geborek P, Saxne T: Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register. Rheumatology 2009;48:243-245.
16. Lutt JR, Deodhar A: Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008;68:591-606.
17. Kaplan GG, Hur C, Korzenik J, Sands BE: Infliximab dose escalation vs initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:1509-1520. (Pubitemid 350178810)